Medical Health & Life Science Research News

Recent research: Glioblastoma multiforme (GBM) - pipeline review, H2 2017

Medical Market Research

The latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2017, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2017 is latest pipeline review released by HTF MI to provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM), complete with analysis by stage of development, drug target, root cause analysis ,mechanism of action (MoA), route of administration (RoA) and molecule type. 


Get Access to Sample PDF @: www.htfmarketreport.com/sample-rep…toma-multiforme-5 Make an Inquiry about this news

If you are want to study the Glioblastoma Multiforme (GBM) or intend to be, then this guide will provide you comprehensive outlook. It’s vital for you to keep your knowledge up to date by keeping research and development (R&D) of major players. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide requirement according to your needs. 

Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy and chemotherapy.

Key Players included in the research study are AbbVie Inc, Accurexa Inc, Actuate Therapeutics Inc, Aduro BioTech Inc, Advantagene Inc, Advenchen Laboratories LLC, Affimed GmbH, Agenus Inc, Ambrx Inc, Amgen Inc, Ampio Pharmaceuticals Inc, AngioChem Inc, Apac Biotech Pvt Ltd, apceth Biopharma GmbH, APIM Therapeutics AS, Apogenix AG, Ariad Pharmaceuticals Inc, Arog Pharmaceuticals Inc, Astellas Pharma Inc, AstraZeneca Plc, Athenex Inc, Basilea Pharmaceutica Ltd, Batu Biologics Inc, Bayer AG, Beactica AB, BeiGene Ltd, Berg LLC, Bexion Pharmaceuticals LLC, BeyondSpring Pharmaceuticals Inc, Bio-Path Holdings Inc, Bioasis Technologies Inc, BioCancell Ltd, Biovista Inc, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Co, Cantex Pharmaceuticals Inc, Cavion LLC, Celgene Corp, Celldex Therapeutics Inc, Cellmid Ltd, Celsion Corp, ChemoCentryx Inc, Coherus BioSciences Inc, Cortice Biosciences Inc, Critical Outcome Technologies Inc, Curtana Pharmaceuticals Inc, Cynata Therapeutics Ltd, CytoVac AS, Daiichi Sankyo Co Ltd, Deciphera Pharmaceuticals LLC, DEKK-TEC Inc, DelMar Pharmaceuticals Inc, Diffusion Pharmaceuticals Inc, Dr. Reddy's Laboratories Ltd, Ecrins Therapeutics SAS, Eisai Co Ltd, Eli Lilly and Co, EnGeneIC Ltd, Enterome Bioscience SA, EntreChem SL, ERC Belgium SA, Erytech Pharma SA, Evotec AG, F-star Biotechnology Ltd, F. Hoffmann-La Roche Ltd, FirstString Research Inc, Fujifilm Holdings Corporation, Gene Techno Science Co Ltd, Genentech Inc, Genisphere LLC, Genor BioPharma Co Ltd, GlaxoSmithKline Plc, GlioPharma ApS, GtreeBNT Co Ltd, GW Pharmaceuticals Plc, Hamlet Pharma AB, Hanmi Pharmaceuticals Co Ltd, Humanigen Inc, Hutchison MediPharma Ltd, Immatics Biotechnologies GmbH, Immune Pharmaceuticals Inc, ImmunoCellular Therapeutics Ltd, Immunomedics Inc, Immunomet Therapeutics Inc, Immunomic Therapeutics Inc, Incyte Corp, Infinity Pharmaceuticals Inc, Innovation Pharmaceuticals Inc, Inovio Pharmaceuticals Inc, Inspyr Therapeutics Inc, Insys Therapeutics Inc, Iovance Biotherapeutics Inc, Ipsen SA, Janpix Inc, Jiangsu Kanion Pharmaceutical Co Ltd, Johnson & Johnson, Juno Therapeutics Inc, Kadmon Corp LLC, Karyopharm Therapeutics Inc, Kazia Therapeutics Ltd, Kite Pharma Inc, Komipharm International Co Ltd, Kringle Pharma Inc, Kyorin Pharmaceutical Co Ltd, Les Laboratoires Servier SAS, Lixte Biotechnology Holdings Inc, Loxo Oncology Inc, Mabion SA, MacroGenics Inc, Medesis Pharma SA, Medicenna Therapeutics Corp, MedImmune LLC, Merck & Co Inc, Merck KGaA, Midatech Pharma Plc, Millennium Pharmaceuticals Inc, MimiVax LLC, Molecular Templates Inc, Moleculin Biotech Inc, Mycenax Biotech Inc, NanoCarrier Co Ltd, Nanomerics Ltd, Nektar Therapeutics, Neonc Technologies Inc, NewLink Genetics Corp, Northwest Biotherapeutics Inc, Novartis AG, Noxopharm Ltd, Noxxon Pharma AG, Nuo Therapeutics Inc, NuvOx Pharma LLC, Omniox Inc, Oncobiologics Inc, Oncodesign SA, Onconova Therapeutics Inc, OncoResponse Inc, Oncternal Therapeutics Inc, Ono Pharmaceutical Co Ltd, Orphit SAS, Oryx GmbH & Co KG, Ovensa Inc, Peloton Therapeutics Inc, Peptomyc SL, Peregrine Pharmaceuticals Inc, Pfizer Inc, Pharma Mar SA, PharmAbcine Inc, PharmaCyte Biotech Inc, Pharmicell Co Ltd, Phoenix Biotechnology Inc, PIQUR Therapeutics AG, Plex Pharmaceuticals Inc, Plexxikon Inc, Prana Biotechnology Ltd, PTC Therapeutics Inc, Puma Biotechnology Inc, Regulus Therapeutics Inc, ReNeuron Group Plc, Rgenix Inc, Richter Gedeon Nyrt, Sanofi, Sapience Therapeutics Inc, Scancell Holdings Plc, Sellas Life Sciences Group Ltd, Sigma-Tau SpA, SignPath Pharma Inc, Silenseed Ltd, SOM Biotech SL, Sorrento Therapeutics Inc, StemGen SpA, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Co Ltd, Sun Pharma Advanced Research Company Ltd, Sunesis Pharmaceuticals Inc, Susavion Biosciences Inc, Symphogen A/S, Synactix Pharmaceuticals Inc, Systimmune Inc, Terpenoid Therapeutics Inc, Theralase Technologies Inc, Therapeia GmbH & Co KG, Tocagen Inc, TRACON Pharmaceuticals Inc, Transgene SA, Trillium Therapeutics Inc, TVAX Biomedical Inc, Tyme Technologies Inc, Upsher-Smith Laboratories Inc, Vascular Biogenics Ltd, Vault Pharma Inc, Vaximm AG, VBI Vaccines Inc, VCN Biosciences SL, ViraTherapeutics GmbH, Vyriad Inc, X4 Pharmaceuticals Inc, Xintela AB, Yooyoung Pharm Co Ltd & ZIOPHARM Oncology Inc. 

Make inquiry @ www.htfmarketreport.com/enquiry-be…toma-multiforme-5 Make an Inquiry about this news 




The guide features dormant and discontinued projects and covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. 


Glioblastoma Multiforme (GBM) pipeline guide helps in identifying and tracking emerging and major players moves in the market and their portfolios, enhances decision making capabilities and helps to create effective marketing strategies to gain competitive advantage in health care and pharmaceuticals industry. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The data and information sourced from the databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the latest key developments are captured on a real time basis. 

Access this research report @ www.htfmarketreport.com/buy-now?fo…amp;report=841033 Make an Inquiry about this news 


Extracts of Chapters from Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2017 
Chapter 1 , to describe the definition , overview and Therapeutics Development of Glioblastoma Multiforme (GBM). 
Chapter2, to analyze the pipeline overview of companies, Universities/Institutes and the product development under by companies, Universities/Institutes. 
Chapter3, Therapeutics Assessment of Glioblastoma Multiforme (GBM) by Target, Mechanism of Action, Route of Administration and by Molecule Type. 
Chapter4, to display company profile involved in Therapeutics Development. 
Chapter5, Drug profile product description, Mechanism of action and R&D Progress of Glioblastoma Multiforme (GBM). 
Chapter 6,7, to describe Glioblastoma Multiforme (GBM) Appendix, Methodology ,Coverage ,Secondary Research ,Primary Research ,Expert Panel Validation and Contact Us. 

Objective of this study 

- To provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM). 
- To reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 
- The pipeline guide features descriptive drug profiles for the pipeline products which comprises, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. 
- The pipeline guide reviews key companies involved in Glioblastoma Multiforme (GBM) therapeutics and enlists all their major and minor projects. 
- The pipeline guide evaluates Glioblastoma Multiforme (GBM) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. 
- The guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM) 

Reasons to access

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. 
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. 
- Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (GBM). 
- Classify potential new clients or partners in the target demographic. 
- Develop tactical initiatives by understanding the focus areas of leading companies. 
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. 
- Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics. 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. 
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. 


Read Detailed Index of full Research Study at @ www.htfmarketreport.com/reports/84…toma-multiforme-5 Make an Inquiry about this news 

News From

HTF Market Intelligence ConsultingHTF Market Intelligence...
Category: Market Research Publishers and RetailersCompany about: HTF Market Report is wholly owned brand of HTF market Intelligence Consulting Private Limited which provides next-generation service for organizations with a deep focus on market intelligence, data analytics, and social intelligence, all uniquely delivered under one roof by skilled professionals. By combining and analyzing acquire lucid and most relevant data which would help in better decision-making. We provide your requirements with speed and cost benefit across the world, we are able to achi ...
This email address is being protected from spambots. You need JavaScript enabled to view it.

For more information:

Make an Inquiry about this report HERE!
  • www.htfmarketreport.com
  • www.htfmarketreport.com/sample-rep…toma-multiforme-5
  • www.htfmarketreport.com/enquiry-be…toma-multiforme-5
  • www.htfmarketreport.com/buy-now?fo…amp;report=841033
  • www.htfmarketreport.com/reports/84…toma-multiforme-5
  • www.linkedin.com/company/13388569